Individual results vary based on starting weight, adherence to treatment, lifestyle factors, and concurrent health conditions
FDA Shortage Update: Why This Still Matters Although the FDA has removed certain GLP-1 medications like Ozempic or Wegovy from its official drug shortage list as of 2024, access challenges and demand surges persist in many real-world settings
GLP-1 receptor agonists function by: Stimulating insulin release when blood sugar levels are high Reducing glucagon secretion, which helps lower blood sugar Slowing gastric emptying, leading to increased satiety Affecting appetite centers in the brain, reducing food intake While these mechanisms contribute to the drugs effectiveness, they may also play a role in potential side effects, including the rare but serious risk of NAION
Longer-term data have also shown that some participants following an intensive protocol lost an average of 26.6% of their body weight, or more than 60 pounds, over roughly two years